Navicixizumab

Mereo BioPharma announces CEO Dr. Denise Scots-Knight's presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The company focuses on rare diseases with candidates like setrusumab for osteogenesis imperfecta and alvelestat for AATD-LD, alongside oncology candidates. Partnerships and designations aim to advance treatments, with forward-looking statements highlighting potential risks and uncertainties.

Mereo BioPharma announced CEO Dr. Denise Scots-Knight will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025. The presentation will be webcast live and archived on the company's website. Mereo focuses on rare diseases, with key products setrusumab and alvelestat, and has partnerships for development and commercialization.

Mereo BioPharma, a biopharmaceutical company specializing in rare diseases, announced CEO Dr. Denise Scots-Knight's presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The company focuses on innovative therapeutics, including setrusumab for osteogenesis imperfecta and alvelestat for AATD-LD, with partnerships and designations from regulatory bodies. Mereo also explores oncology treatments and has global licensing agreements for its product candidates.

Mereo BioPharma's CEO, Dr. Denise Scots-Knight, to participate in a Fireside Chat at the Jefferies London Healthcare Conference on Nov 19, 2024, at 10:30am ET / 03:30pm GMT. Live audio webcast available on the Company’s website, with an archived replay for two weeks.